The purpose of the Genomics Facility is to provide routine and state of the art genomic technologies to support cutting edge genomics research of the Cancer Center. Routine DNA sequencing provides DNA sequence of new DNA clones and recombinant vectors. Additional services focus on new or complex genomic technologies that can not be readily developed in a single laboratory, especially given the rapid technological advancements in this technical area. The Genomics Facility has changed considerably over the past several years to keep pace with the changing needs of Center members and the rapid growth in new genomic technologies. The Cancer Center has recently purchased an Illumina (Solexa) Genome Analyzer, and, through an NCI small equipment grant, an Illumina BeadStation. This grant was facilitated by a Cancer Center pilot grant that facilitated the development of a high throughput PCR platform. The Facility is widely used by all three research programs and almost every Cancer Center investigator. Although many larger institutions separate the sequencing and genomics functions, the Facility has developed a working model to combine the services effectively, primarily through cross-training of facility personnel. This approach provides stability and efficiency. The Facility treats DNA sequencing and the various genomics activities as separate services. The Illumina Genome Analyzer applications have been added to services provided by the Genomics Facility. During the next funding period, the Facility will introduce multiple approaches to monitoring epigenetic changes with the Illumina Genome Analyzer and Illumina promoter methylation arrays. In response to a significant interest of Center members in microRNA (miRNA) functions in development and disease, a high throughput Illumina miRNA platform will be established to complement the ABI low density miRNA arrays presently being used by the facility. Future plans also include the development of protocols that will allow investigators to look at gene expression in small numbers of cells, such as various types of stem cells.
The ability to determine the DNA sequence of cloned DNA and to now perform deep DNA sequence determination are fundamental tools of modern cancer biology. Analysis of gene expression patterns for number of genes in a single experiment promises to help elucidate the changes in networks that will help to target cancer therapeutics to the most critical point in these networks and to characterize cancers.
|Tomescu, Costin; Tebas, Pablo; Montaner, Luis J (2017) IFN-? augments NK-mediated antibody-dependent cellular cytotoxicity (ADCC) of HIV-1 infected autologous CD4+ T cells regardless of MHC-I downregulation. AIDS :|
|Vitiello, Marianna; Tuccoli, Andrea; D'Aurizio, Romina et al. (2017) Context-dependent miR-204 and miR-211 affect the biological properties of amelanotic and melanotic melanoma cells. Oncotarget 8:25395-25417|
|Veglia, Filippo; Gabrilovich, Dmitry I (2017) Dendritic cells in cancer: the role revisited. Curr Opin Immunol 45:43-51|
|Hoffman, Hunter; Rice, Cory; Skordalakes, Emmanuel (2017) Structural Analysis Reveals the Deleterious Effects of Telomerase Mutations in Bone Marrow Failure Syndromes. J Biol Chem 292:4593-4601|
|Lu, Fang; Wiedmer, Andreas; Martin, Kayla A et al. (2017) Coordinate Regulation of TET2 and EBNA2 Control DNA Methylation State of Latent Epstein-Barr Virus. J Virol :|
|Karpel-Massler, Georg; Ishida, Chiaki Tsuge; Bianchetti, Elena et al. (2017) Inhibition of Mitochondrial Matrix Chaperones and Antiapoptotic Bcl-2 Family Proteins Empower Antitumor Therapeutic Responses. Cancer Res 77:3513-3526|
|Lynch, Shannon M; Mitra, Nandita; Ravichandran, Krithika et al. (2017) Telomere Length and Neighborhood Circumstances: Evaluating Biological Response to Unfavorable Exposures. Cancer Epidemiol Biomarkers Prev 26:553-560|
|Perales-Puchalt, Alfredo; Svoronos, Nikolaos; Rutkowski, Melanie R et al. (2017) Follicle-Stimulating Hormone Receptor Is Expressed by Most Ovarian Cancer Subtypes and Is a Safe and Effective Immunotherapeutic Target. Clin Cancer Res 23:441-453|
|Pestell, Timothy G; Jiao, Xuanmao; Kumar, Mukesh et al. (2017) Stromal cyclin D1 promotes heterotypic immune signaling and breast cancer growth. Oncotarget 8:81754-81775|
|Noguchi, Shuhei; Arakawa, Takahiro; Fukuda, Shiro et al. (2017) FANTOM5 CAGE profiles of human and mouse samples. Sci Data 4:170112|
Showing the most recent 10 out of 685 publications